Candesartan restores pressure-induced vasodilation and prevents skin pressure ulcer formation in diabetic mice

Cardiovascular Diabetology

Claire Demiot¹  Jean-Michel Achard²  Nicole Oudart²  James Javellaud²  Flavien Bessaguet¹  Mohamad Nasser²  Aurore Danigo¹ 

[1] EA6309, School of Medecine and Pharmacy, University of Limoges, Limoges Cedex, 87025, France;EA3842, School of Medecine and Pharmacy, University of Limoges, Limoges Cedex, 87025, France

关键词: Pressure ulcer;    Streptozotocin;    Pressure-induced vasodilation;    Candesartan;   

Others  :  1172642
DOI  :  10.1186/s12933-015-0185-4

 received in 2014-11-21, accepted in 2015-01-27,  发布年份 2015

【 摘 要 】

Background

Angiotensin II type 1 receptor (AT1R) blockers have beneficial effects on neurovascular complications in diabetes and in organ’s protection against ischemic episodes. The present study examines whether the AT1R blocker candesartan (1) has a beneficial effect on diabetes-induced alteration of pressure-induced vasodilation (PIV, a cutaneous physiological neurovascular mechanism which could delay the occurrence of tissue ischemia), and (2) could be protective against skin pressure ulcer formation.

Methods

Male Swiss mice aged 5–6 weeks were randomly assigned to four experimental groups. In two groups, diabetes was induced by a single intraperitoneal injection of streptozotocin (STZ, 200 mg.kg⁻¹). After 6 weeks, control and STZ mice received either no treatment or candesartan (1 mg/kg-daily in drinking water) during 2 weeks. At the end of treatment (8 weeks of diabetes duration), C-fiber mediated nociception threshold, endothelium-dependent vasodilation and PIV were assessed. Pressure ulcers (PUs) were then induced by pinching the dorsal skin between two magnetic plates for three hours. Skin ulcer area development was assessed during three days, and histological examination of the depth of the skin lesion was performed at day three.

Results

After 8 weeks of diabetes, the skin neurovascular functions (C-fiber nociception, endothelium-dependent vasodilation and PIV) were markedly altered in STZ-treated mice, but were fully restored by treatment with candesartan. Whereas in diabetes mice exposure of the skin to pressure induced wide and deep necrotic lesions, treatment with candersartan restored their ability to resist to pressure-induced ulceration as efficiently as the control mice.

Conclusion

Candesartan decreases the vulnerability to pressure-induced ulceration and restores skin neurovascular functions in mice with STZ-induced established diabetes.

【 授权许可】

   
2015 Danigo et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Adler AI, Boyko EJ, Ahroni JH, Smith DG: Lower-extremity amputation in diabetes. The independent effects of peripheral vascular disease, sensory neuropathy, and foot ulcers. Diabetes Care 1999, 22(7):1029-35.
• [2]Demiot C, Sarrazy V, Javellaud J, Gourloi L, Botelle L, Oudart N, et al.: Erythropoietin restores C-fiber function and prevents pressure ulcer formation in diabetic mice. J Invest Dermatol 2011, 131(11):2316-22.
• [3]Fromy B, Merzeau S, Abraham P, Saumet JL: Mechanisms of the cutaneous vasodilator response to local external pressure application in rats: involvement of CGRP, neurokinins, prostaglandins and NO. Br J Pharmacol 2000, 131(6):1161-71.
• [4]Fromy B, Abraham P, Saumet JL: Non-nociceptive capsaicin-sensitive nerve terminal stimulation allows for an original vasodilatory reflex in the human skin. Brain Res 1998, 811(1–2):166-8.
• [5]Fromy B, Lingueglia E, Sigaudo-Roussel D, Saumet JL, Lazdunski M: Asic3 is a neuronal mechanosensor for pressure-induced vasodilation that protects against pressure ulcers. Nat Med 2012, 18(8):1205-7.
• [6]Demiot C, Fromy B, Saumet JL, Sigaudo-Roussel D: Preservation of pressure-induced cutaneous vasodilation by limiting oxidative stress in short-term diabetic mice. Cardiovasc Res 2006, 69(1):245-52.
• [7]Koitka A, Abraham P, Bouhanick B, Sigaudo-Roussel D, Demiot C, Saumet JL: Impaired pressure-induced vasodilation at the foot in young adults with type 1 diabetes. Diabetes 2004, 53(3):721-5.
• [8]American Diabetes Association: Standards of medical care in diabetes-2014 Diabetes Care 2014, 37(Suppl 1):S14-80.
• [9]Cameron NE, Cotter MA, Robertson S: Angiotensin converting enzyme inhibition prevents development of muscle and nerve dysfunction and stimulates angiogenesis in streptozotocin-diabetic rats. Diabetologia 1992, 35(1):12-8.
• [10]Cameron NE, Cotter MA, Robertson S: Rapid reversal of a motor nerve conduction deficit in streptozotocin-diabetic rats by the angiotensin converting enzyme inhibitor lisinopril. Acta Diabetol 1993, 30(1):46-8.
• [11]Maxfield EK, Cameron NE, Cotter MA, Dines KC: Angiotensin II receptor blockade improves nerve function, modulates nerve blood flow and stimulates endoneurial angiogenesis in streptozotocin-diabetic rats and nerve function. Diabetologia 1993, 36(12):1230-7.
• [12]Coppey LJ, Davidson EP, Rinehart TW, Gellett JS, Oltman CL, Lund DD, et al.: ACE inhibitor or angiotensin II receptor antagonist attenuates diabetic neuropathy in streptozotocin-induced diabetic rats. Diabetes 2006, 55(2):341-8.
• [13]Sugimoto K, Kojima K, Baba M, Yasujima M: Olmesartan ameliorates peripheral nerve dysfunction in Zucker diabetic fatty rats. J Hypertens 2011, 29(7):1337-46.
• [14]Malik RA, Williamson S, Abbott C, Carrington AL, Iqbal J, Schady W, et al.: Effect of angiotensin-converting-enzyme (ACE) inhibitor trandolapril on human diabetic neuropathy: randomised double-blind controlled trial. Lancet 1998, 352(9145):1978-81.
• [15]Demiot C, Tartas M, Fromy B, Abraham P, Saumet JL, Sigaudo-Roussel D: Aldose reductase pathway inhibition improved vascular and C-fiber functions, allowing for pressure-induced vasodilation restoration during severe diabetic neuropathy. Diabetes 2006, 55(5):1478-83.
• [16]Stadler I, Zhang RY, Oskoui P, Whittaker MS, Lanzafame RJ: Development of a simple, noninvasive, clinically relevant model of pressure ulcers in the mouse. J Invest Surg 2004, 17(4):221-7.
• [17]Tsuji S, Ichioka S, Sekiya N, Nakatsuka T: Analysis of ischemia-reperfusion injury in a microcirculatory model of pressure ulcers. Wound Repair Regen 2005, 13(2):209-15.
• [18]Kietadisorn R, Juni R, Moens A: Tackling endothelial dysfunction by modulating NOS uncoupling: new insights into its pathogenesis and therapeutic possibilities. Am J Physiol Endocrinol Metab 2012, 302(5):E481-95.
• [19]Förstermann U: Janus-faced role of endothelial NO synthase in vascular disease: uncoupling of oxygen reduction from NO synthesis and its pharmacological reversal. Biol Chem 2006, 387(12):1521-33.
• [20]Kuno A, Miura T, Tsuchida A, Hasegawa T, Miki T, Nishino Y, et al.: Blockade of angiotensin II type 1 receptors suppressed free radical production and preserved coronary endothelial function in the rabbit heart after myocardial infarction. J Cardiovasc Pharmacol 2002, 39(1):49-57.
• [21]Knorr M, Hausding M, Kroller-Schuhmacher S, Steven S, Oelze M, Heeren T, et al.: Nitroglycerin-induced endothelial dysfunction and tolerance involve adverse phosphorylation and S-Glutathionylation of endothelial nitric oxide synthase: beneficial effects of therapy with the AT1 receptor blocker telmisartan. Arterioscler Thromb Vasc Biol 2011, 31(10):2223-31.
• [22]Nevelsteen I, Van den Bergh A, Van der Mieren G, Vanderper A, Mubagwa K, Bult H, et al.: NO-dependent endothelial dysfunction in type II diabetes is aggravated by dyslipidemia and hypertension, but can be restored by angiotensin-converting enzyme inhibition and weight loss. J Vasc Res 2013, 50(6):486-97.
• [23]Matsumoto S, Shimabukuro M, Fukuda D, Soeki T, Yamakawa K, Masuzaki H, et al.: Azilsartan, an angiotensin II type 1 receptor blocker, restores endothelial function by reducing vascular inflammation and by increasing the phosphorylation ratio Ser(1177)/Thr(497) of endothelial nitric oxide synthase in diabetic mice. Cardiovasc Diabetol 2014, 13:30. BioMed Central Full Text
• [24]Cavka A, Cosic A, Grizelj I, Koller A, Jelakovic B, Lombard JH, et al.: Effects of AT1 receptor blockade on plasma thromboxane A2 (TXA2) level and skin microcirculation in young healthy women on low salt diet. Kidney Blood Press Res 2013, 37(4–5):432-42.
• [25]Joannides R, Bizet-Nafeh C, Costentin A, Iacob M, Derumeaux G, Cribier A, et al.: Chronic ACE inhibition enhances the endothelial control of arterial mechanics and flow-dependent vasodilatation in heart failure. Hypertension 2001, 38(6):1446-50.
• [26]Perrone-Filardi P, Corrado L, Brevetti G, Silvestro A, Dellegrottaglie S, Cafiero M, et al.: Effects of AT1 receptor antagonism with candesartan on endothelial function in patients with hypertension and coronary artery disease. J Clin Hypertens (Greenwich) 2009, 11(5):260-5.
• [27]Zankl AR, Ivandic B, Andrassy M, Volz HC, Krumsdorf U, Blessing E, et al.: Telmisartan improves absolute walking distance and endothelial function in patients with peripheral artery disease. Clin Res Cardiol 2010, 99(12):787-94.
• [28]Benndorf RA, Appel D, Maas R, Schwedhelm E, Wenzel UO, Boger RH: Telmisartan improves endothelial function in patients with essential hypertension. J Cardiovasc Pharmacol 2007, 50(4):367-71.
• [29]Iino K, Watanabe H, Iino T, Katsuta M, Koyama T, Kosaka T, et al.: Candesartan improves impaired endothelial function in the human coronary artery. Coron Artery Dis 2012, 23(4):278-83.
• [30]Chang CH, Chang YC, Wu LC, Lin JW, Chuang LM, Lai MS: Different angiotensin receptor blockers and incidence of diabetes: a nationwide population-based cohort study. Cardiovasc Diabetol 2014, 13:91. BioMed Central Full Text
• [31]Uehara K, Yamagishi S, Otsuki S, Chin S, Yagihashi S: Effects of polyol pathway hyperactivity on protein kinase C activity, nociceptive peptide expression, and neuronal structure in dorsal root ganglia in diabetic mice. Diabetes 2004, 53(12):3239-47.
• [32]Vinik AI, Mehrabyan A: Diabetic neuropathies. Med Clin North Am 2004, 88(4):947-99. xi
• [33]Beiswenger KK, Calcutt NA, Mizisin AP: Dissociation of thermal hypoalgesia and epidermal denervation in streptozotocin-diabetic mice. Neurosci Lett 2008, 442(3):267-72.
• [34]Shakher J, Stevens MJ: Update on the management of diabetic polyneuropathies. Diabetes Metab Syndr Obes 2011, 4:289-305.
• [35]Oprisiu-Fournier R, Faure S, Mazouz H, Boutitie F, Serot JM, Achard JM, et al.: Angiotensin AT1-receptor blockers and cerebrovascular protection: do they actually have a cutting edge over angiotensin-converting enzyme inhibitors? Expert Rev Neurother 2009, 9(9):1289-305.
• [36]McCarthy CA, Vinh A, Callaway JK, Widdop RE: Angiotensin AT2 receptor stimulation causes neuroprotection in a conscious rat model of stroke. Stroke 2009, 40(4):1482-9.
• [37]Faure S, Bureau A, Oudart N, Javellaud J, Fournier A, Achard JM: Protective effect of candesartan in experimental ischemic stroke in the rat mediated by AT2 and AT4 receptors. J Hypertens 2008, 26(10):2008-15.
• [38]Mogi M, Li JM, Iwanami J, Min LJ, Tsukuda K, Iwai M, et al.: Angiotensin II type-2 receptor stimulation prevents neural damage by transcriptional activation of methyl methanesulfonate sensitive 2. Hypertension 2006, 48(1):141-8.
• [39]Hamai M, Iwai M, Ide A, Tomochika H, Tomono Y, Mogi M, et al.: Comparison of inhibitory action of candesartan and enalapril on brain ischemia through inhibition of oxidative stress. Neuropharmacology 2006, 51(4):822-8.
• [40]Li J, Culman J, Hortnagl H, Zhao Y, Gerova N, Timm M, et al.: Angiotensin AT2 receptor protects against cerebral ischemia-induced neuronal injury. FASEB J 2005, 19(6):617-9.
• [41]Iwai M, Liu HW, Chen R, Ide A, Okamoto S, Hata R, et al.: Possible inhibition of focal cerebral ischemia by angiotensin II type 2 receptor stimulation. Circulation 2004, 110(7):843-8.
• [42]Faure S, Chapot R, Tallet D, Javellaud J, Achard J, Oudart N: Cerebroprotective effect of angiotensin IV in experimental ischemic stroke in the rat mediated by AT(4) receptors. J Physiol Pharmacol 2006, 57(3):329-42.
• [43]Faure S, Oudart N, Javellaud J, Fournier A, Warnock D, Achard J: Synergistic protective effects of erythropoietin and olmesartan on ischemic stroke survival and post-stroke memory dysfunctions in the gerbil. J Hypertens 2006, 24(11):2255-61.
• [44]Krikov M, Thone-Reineke C, Muller S, Villringer A, Unger T: Candesartan but not ramipril pretreatment improves outcome after stroke and stimulates neurotrophin BNDF/TrkB system in rats. J Hypertens 2008, 26(3):544-52.
• [45]Margolis DJ, Hoffstad O, Thom S, Bilker W, Maldonado AR, Cohen RM, et al.: The differential effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers with respect to foot ulcer and limb amputation in those with diabetes. Wound Repair Regen 2010, 18(5):445-51.
• [46]Wrobel JS, Mayfield JA, Reiber GE: Geographic variation of lower-extremity major amputation in individuals with and without diabetes in the Medicare population. Diabetes Care 2001, 24(5):860-4.
• [47]Engelgau MM, Geiss LS, Saaddine JB, Boyle JP, Benjamin SM, Gregg EW, et al.: The evolving diabetes burden in the United States. Ann Intern Med 2004, 140(11):945-50.